Sedana Medical AB (publ), First Quarter Report 2021
Regulatory
A quarter of launch preparations and continued increase in sales, lifted by the pandemic
Sedana Medical publishes its Annual Report 2020
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announces that its Annual Report for 2020 has been published.
Notice of Annual General Meeting in Sedana Medical AB (publ)
Regulatory
The shareholders in Sedana Medical AB (publ), reg. no. 556670-2519, are hereby given notice to attend the annual general meeting to be held on Monday 10 May 2021. In order counteract the spreading of the corona virus, the board of directors of the co…
The nomination committee’s proposal in respect of election of board members at the annual general meeting of Sedana Medical
Regulatory
The nomination committee of Sedana Medical AB (publ) (SEDANA: FN Stockholm) has presented its proposal in respect of election of board members at the annual general meeting to be held May 10, 2021. The nomination committee proposes re-election of all…
Sedana Medical AB (publ), Fourth Quarter and Year-end Report
Regulatory
Registration application submitted in the EU – strong sales increase as a result of COVID-19
Sedana Medical's CEO Christer Ahlberg is leaving the company
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that Christer Ahlberg has informed the board of directors of Sedana Medical that he is resigning as CEO to become CEO of Cinclus Pharma AB. Christer Ahlberg will remain as CEO until the…
First patient included in pediatric study IsoCOMFORT
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the first patient has been included in the company's pediatric study IsoCOMFORT (SED002) which is conducted to investigate if inhaled sedation of Sedaconda (isoflurane) via AnaConDa…
Sedana Medical submits application for market approval in UK
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for market approval for the drug candidate Sedaconda (isoflurane) for inhaled sedation in intensive care in the UK.
Sedana Medical submits application for marketing approval in Switzerland
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for marketing approval for the drug candidate Sedaconda (isoflurane), formerly known as IsoConDa, for inhaled sedation in intensive care in…
Sedana Medical presents research grant recipients 2020
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced the recipients of the Sedana Medical Research Grant 2020. The grant is a unique opportunity for the scientific community to increase knowledge of sedation therapies of critically ill pat…
Sedana Medical’s Sedaconda study presented at ESICM
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that outcomes from some of the secondary endpoints of the company’s pivotal study, Sedaconda (SED-001, formerly known as the IsoConDa-study) were presented at the leading congress ESICM…
Sedana Medical submits market approval application for the drug Sedaconda
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has submitted an application for market approval for the drug candidate Sedaconda (isoflurane), formerly known as IsoConDa, for inhaled sedation in intensive care. The a…
Sedana Medical receives additional patent for AnaConDa
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has been granted another patent regarding the medical device AnaConDa. The technology that the patent protects enables a reduction of the so-called dead space with the h…
Sedana Medical AB (publ), interim report Q3, 2020
Regulatory
Positive clinical study – on the way towards our vision
Sedana Medical’s nomination committee appointed
Regulatory
Sedana Medical AB (publ) today publish that in accordance with the resolution of the Annual General Meeting on May 19, 2020, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes t…
AnaConDa from Sedana Medical reviewed by NICE in UK
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the UK's National Institute for Health and Care Excellence (NICE) has issued a Medtech innovation briefing (MIB) on the use of AnaConDa as an alternative to intravenous sedation in…
Sedana Medical appoints new CFO
Regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that Susanne Andersson has been appointed new CFO and will take office during the first quarter of 2021. Susanne Andersson succeeds Maria Engström, who on her own initiative has chosen t…
Sedana Medical's CEO divests shares – remains a committed and long-term shareholder
Non-regulatory
Christer Ahlberg, CEO of Sedana Medical AB, has informed the company that he has sold 75 000 shares in Sedana Medical, representing approximately 0.33% of the total outstanding number of shares and 22.5% of his total shareholding in the company. Foll…
Sedana Medical AB (publ), interim report Q2, 2020
Regulatory
All-time-high sales and positive study result
Sedana Medical signs distribution agreement in Australia and New Zeeland
Non-regulatory
Sedana Medical AB (publ) (SEDANA: FN Stockholm) today announced that the company has signed a distribution agreement for sales in Australia and New Zeeland with the distributor Device Technologies. As the AnaConDa already has market approval in both…